AtriCure’s AtriClip Receives Expanded CE Mark Indication for Stroke Reduction in Patients With AFib

August 22, 2024—AtriCure, Inc. announced that it has received an expanded CE Mark indication for the AtriClip in Europe. The device is now indicated for use in patients at high risk of thromboembolism for whom left atrial appendage (LAA) exclusion is warranted.

According to the company, the AtriClip family of devices is designed to exclude, electrically isolate, and eventually eliminate the LAA during cardiac surgery. The company noted that the LAA is a major source of blood clots in patients with atrial fibrillation. The expanded indication is a result of clinical evidence and real-world experience demonstrating a reduction in stroke events for patients who receive an AtriClip device.

“I’ve been using AtriClip devices for over a decade and have seen firsthand the benefits of its safety and efficacy,” said Professor Nicolas Doll, MD, in AtriCure’s press release. Prof. Doll, Chief Physician of Cardiac Surgery at Schuechtermann-Clinic in Bad Rothenfelde, Germany, added, “The devices are easy to use, and they provide patients with the benefit of long-term prevention of stroke, which makes adoption of the AtriClip an easy decision.”